解渤 Ph.D.

Chairman, 重生医药

Authority on Shanghan medicine

Doctor of Chinese Medicine, trained in the United States

In 2015 he returned to China and founded 瑞博健康 , focusing on chronic-disease management. In 2021 he founded 苏州重生医药科技 . He received the Suzhou Leading Talent title (苏州领军人才) and led the development of the world's first innovative drug for arterial plaque. He holds more than 70 invention patents. Bringing together pharmaceutical research teams in China and the United States, he has advanced the development of multiple Class 1.1 innovative drugs in both new Chinese-herbal medicines and biopharmaceuticals. Major breakthroughs have been made in heart failure, coronary heart disease, mental illness, and degenerative brain diseases.

解渤 was born into a family of Chinese-medicine practitioners. He is a descendant of 解德明, known as “圣手先生” at 同义堂 in the late Qing dynasty, and the last disciple of 曾荣修, a master of Shanghan medicine. He has practiced for more than 30 years. He studied the classic formulas and pulse methods of the Shanghan school under 曾荣修, master of the 田曾 lineage (田曾流), and received the core of that lineage’s Shanghan pattern system, which takes pulse study as its basis and its standard: “Where that pulse is present, use that formula.” He set out the mathematical logic of the Hetu and the Luoshu and the foundations of Chinese medicine. He founded the “天道养生” school, bringing herbal medicine, pulse-based formulas, acupuncture, diet, exercise, and daily routine into one practice. Through more than 20 years of theoretical study and clinical work, combined with modern technology, he developed an efficient treatment and management program for metabolic conditions including heart failure, cerebellar atrophy, type 2 diabetes, pulmonary nodules, arterial plaque, and hyperlipidemia.

解涛 Ph.D.

Chief Medical Officer, 太一集团

Authority on Shanghan medicine

Doctor of Chinese Medicine, trained in the United States

He comes from a family of Chinese-medicine practitioners and is a descendant of 解德明, known as “圣手先生” at 同义堂 in the late Qing dynasty, carrying a deep grounding in Chinese medicine and its transmission. He studied under 曾荣修, master of the Shanghan school's 田曾 lineage (田曾流), and studied the essence of Chinese medicine in depth. In his youth he moved with his family to California, continued advanced study, and earned a master's degree and a doctorate. He obtained a California Chinese-medicine practitioner license, operated a Chinese-medicine clinic, and accumulated substantial clinical experience.

He has taken part in studying and developing the “天道养生” theoretical system of Chinese medicine, and works to combine traditional Chinese-medicine knowledge with modern medicine. He has practiced for nearly 30 years, sought out noted physicians, and continued to improve his clinical skill, with substantial experience especially in chronic endocrine disease. In 2017 he returned to China and joined his elder brother, 解渤, in the health enterprise. He became Chief Medical Officer of 太一集团 and took overall charge of its medical work. In 2021 he was invited to see patients at Shenzhen Private Banking of China Construction Bank (深圳建行私人银行), and also served as a specially appointed expert for 平安乐健康.

In clinical practice he has continued to innovate and refine his medicine, and has introduced a number of distinct treatment programs for serious and difficult illnesses. In the diagnosis and treatment of major and chronic conditions, including type 2 diabetes, arterial plaque, heart failure, and pulmonary nodules, he has achieved significant results and brought patients new hope and a new chance.